Subscribe
gowithstock
gowithstock / shutterstock.com
30 April 2020Biotechnology

Oxford secures industry partner for potential vaccine rollout

The  University of Oxford has partnered with UK pharmaceutical company  AstraZeneca to develop and manufacture the university’s trial COVID-19 vaccine.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission
1 February 2021   The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

article
LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission
1 February 2021   The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

More on this story

article
LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission
1 February 2021   The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

More features

Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages
Judge denies Intellia bid to throw out suit over $100m Regeneron pact
‘AI curious’ counsel at AZ, Novartis weigh risks and benefits
Trump’s return sparks calls for pro-patent agenda
EOFlow ordered to pay rival $452m over insulin patch trade secrets
Amgen faces pushback over bid to narrow patent scope